Australia markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
29.08+1.14 (+4.08%)
At close: 04:00PM EDT
29.37 +0.29 (+1.00%)
After hours: 04:44PM EDT

Jasper Therapeutics, Inc.

2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400
https://www.jaspertherapeutics.com/

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees45

Key executives

NameTitlePayExercisedYear born
Mr. Ronald A. MartellPresident, CEO & Director892.45kN/A1962
Dr. Judith Anne Shizuru M.D., Ph.D.Co-Founder, Chair of Scientific Advisory Board & Director291.25kN/A1956
Mr. Jeetinder Singh Mahal M.B.A.Chief Operating Officer579.46kN/A1972
Mr. Herbert C. CrossCFO & Corporate SecretaryN/AN/A1972
Dr. Luca Di Noto Ph.D.Senior Vice President of Technical OperationsN/AN/AN/A
Mr. David Ku M.D.Vice President of Corporate Development, Portfolio Strategy & ManagementN/AN/AN/A
Mr. Matthew FordVice President of Human ResourcesN/AN/AN/A
Dr. Wendy Pang M.D., Ph.D.Senior Vice President of Research & Translational MedicineN/AN/AN/A
Dr. Edwin Jonathan Tucker M.D.Chief Medical OfficerN/AN/A1972
Ms. Patricia CarlosSenior Vice President of Regulatory Affairs & QualityN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Corporate governance

Jasper Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.